Astellas and Seattle Genetics Inc. recently unveiled updated testing data from Phase 1 of a test of enfortumab vetodin.
The companies discussed the data at the 52nd annual American Society of Clinical Oncology meeting in Chicago.
Enfortumab vetodin is being tested as a monotherapy to fight metastatic urothelial cancer, according to a press release. In the data that Astellas and Seattle Genetics presented, 71 percent of those using enfortumab vetodin and who were tested to see how their bodies reacted to the enfortumab vetodin had the metastatic urothelial cancer under control. The companies reported that the side effects they found most often through the test group were nausea, badly itchy skin, fatigue and diarrhea. According to the data the companies presented, 36 percent of the group had nausea, 31 percent had the skin itch, 30 percent were fatigued and 28 percent suffered diarrhea.
According to the Astellas and Seattle Genetics data, 19 people who had metastases on their liver are part of the test group, and 68 percent of them saw the disease become under control.
Astellas and Seattle Genetics reported that they were presenting data from a test group of 81 metastatic urothelial cancer sufferers, half of whom were under 67 years old and half were over 67 years old.
